We then assess TH1/17 cells in patients with MS and find reduced expression of anti-inflammatory IL10 and elevated expression of CXCR3. When we compare clinically active vs. stable patients, we find that stable patients have higher IL10 expression in TH17 cells, whereas active patients have higher expression of STAT3 in IFN-γ–/IL-17– CD4+ T cells. This evidence concerns the gene IFNG and myeloid sarcoma.